title: Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
abstract: OBJECTIVE
  Glucagon-like peptide 1 receptor agonists (GLP-1 RA) stimulate satiety leading to reductions in food intake and body weight. The effects of long- acting GLP-1 RA liraglutide on eating behavior of women with PCOS have not been investigated yet.
  
  
  METHODS
  Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks. Adiposity parameters and eating behavior as assessed by Three-Factor Eating Questionnaire (TFEQ-R18) were examined at baseline and after 12 weeks.
  
  
  RESULTS
  Subjects treated with liraglutide lost on average 3.8 ± 0.1 kg (p < 0.001). Significant reductions of waist circumference and visceral adipose tissue (VAT) mass, volume and area were demonstrated from liraglutide induction to the end of the study. TFEQ-R18 scores were significantly different pre- and post-liraglutide intervention. After treatment with liraglutide the uncontrolled eating (UE) score decreased from 36.8 ± 24.5 to 19.6 ± 18.4 (p < 0.001) and emotional eating (EE) score decreased from 49.9 ± 33.3 to 28.5 ± 26.9 (p < 0.001). Scores for cognitive restraint (CR) were not changed.
  
  
  CONCLUSIONS
  Short-term liraglutide treatment was associated with weight loss and significantly improved eating behavior in obese women with PCOS.
authors.affiliation: Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana , Ljubljana , Slovenia.
authors.forename: Mojca
authors.initials: M
authors.lastname: Jensterle
authors.forename: Tomaz
authors.initials: T
authors.lastname: Kocjan
authors.forename: Nika Aleksandra
authors.initials: NA
authors.lastname: Kravos
authors.forename: Marija
authors.initials: M
authors.lastname: Pfeifer
authors.forename: Andrej
authors.initials: A
authors.lastname: Janez
mesh_terms: D000328:Adult; D001786:Blood Glucose; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D050152:Intra-Abdominal Fat / Q000473:pathology; D000069450:Liraglutide / Q000494:pharmacology / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D055105:Waist Circumference; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D000069450:Liraglutide
keywords: Eating behavior; PCOS; TFEQ-R18; liraglutide; obesity